Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 With or Without Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
jRCT2021250056Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of PF-08634404 and enfortumab vedotin in transitional cell carcinoma (TCC) and urothelial carcinoma (UC) (2 arms), sponsored by Pfizer. Primary endpoints: Confirmed Objective Response Rate (ORR) by investigator, Number of participants with treatment-emergent adverse events and serious adverse events and 1 more. Started May 2026; status: recruiting.
02
Drugs
PF-08634404enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on jRCT2021250056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250056.